Bone-regulator antibody
Antibody bone-regulator neutralization
- Neutralizes a regulatory signal at bone rather than acting on the osteoclast directly
- Denosumab binds RANKL, so RANK is never activated and osteoclasts do not form or survive
- Romosozumab binds sclerostin, which BUILDS bone — the opposite direction, same family
- Neutralizes a regulatory signal at bone rather than acting on the osteoclast directly
- Denosumab binds RANKL, so RANK is never activated and osteoclasts do not form or survive
- Romosozumab binds sclerostin, which BUILDS bone — the opposite direction, same family
Drugs with this mechanism (2)
- Denosumab — RANKL antibody for osteoporosis; rebound fractures follow abrupt discontinuation.
- Romosozumab — Sclerostin antibody that builds bone and resorbs less; boxed CV warning.
All mechanisms · Open Antibody bone-regulator neutralization in the interactive console ↗